Omnicell (NASDAQ:OMCL) Stock Rating Upgraded by Zacks Research

Omnicell (NASDAQ:OMCL) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday, Zacks reports.

A number of other brokerages also recently commented on OMCL. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Wells Fargo & Company lowered their price target on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Stock Performance

Shares of OMCL opened at $33.88 on Monday. Omnicell has a 1 year low of $29.06 and a 1 year high of $55.00. The company’s 50 day simple moving average is $39.06 and its 200 day simple moving average is $39.21. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of 40.33, a PEG ratio of 0.86 and a beta of 0.97. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.47 by $0.47. The firm had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. Omnicell’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, sell-side analysts predict that Omnicell will post 1.41 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Nykredit A S acquired a new position in Omnicell in the second quarter valued at $26,000. Raymond James Financial Inc. acquired a new stake in Omnicell during the second quarter worth about $26,000. Versant Capital Management Inc raised its holdings in shares of Omnicell by 38.7% in the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after purchasing an additional 294 shares during the period. Clearstead Advisors LLC raised its holdings in shares of Omnicell by 12,180.0% in the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after purchasing an additional 1,218 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Omnicell in the 4th quarter valued at about $58,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.